GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Cash Flow from Investing

aTyr Pharma (aTyr Pharma) Cash Flow from Investing : $-20.13 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, aTyr Pharma spent $0.02 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $9.67 Mil on purchasing investments. It gained $27.50 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, aTyr Pharma gained $17.82 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


aTyr Pharma Cash Flow from Investing Historical Data

The historical data trend for aTyr Pharma's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Cash Flow from Investing Chart

aTyr Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.93 6.90 -91.57 47.25 -20.13

aTyr Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 -38.17 -4.16 4.38 17.82

aTyr Pharma Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

aTyr Pharma's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

aTyr Pharma's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


aTyr Pharma  (NAS:LIFE) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

aTyr Pharma's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.02 Mil. It means aTyr Pharma spent $0.02 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

aTyr Pharma's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means aTyr Pharma gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

aTyr Pharma's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means aTyr Pharma spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

aTyr Pharma's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means aTyr Pharma gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

aTyr Pharma's purchase of investment for the three months ended in Dec. 2023 was $-9.67 Mil. It means aTyr Pharma spent {stock_data.stock.currency_symbol}}9.67 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

aTyr Pharma's sale of investment for the three months ended in Dec. 2023 was $27.50 Mil. It means aTyr Pharma gained $27.50 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

aTyr Pharma's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means aTyr Pharma paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

aTyr Pharma's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means aTyr Pharma paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

aTyr Pharma's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means aTyr Pharma paid $0.00 Mil for other investing activities.


aTyr Pharma Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (aTyr Pharma) Business Description

Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121

aTyr Pharma (aTyr Pharma) Headlines

From GuruFocus

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-25-2023